Cervical intraepithelial neoplasia is associated with genital tract mucosal inflammation

Sexually Transmitted Diseases

Volumn 39, Issue 8, 2012, Pages 591-597

  Mhatre, Mohak ^a   McAndrew, Thomas ^a   Carpenter, Colleen ^a   Burk, Robert D ^a   Einstein, Mark H ^a   Herold, Betsy C ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA DEFENSIN 2; BETA DEFENSIN 3; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; POLYPEPTIDE ANTIBIOTIC AGENT; RANTES; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ESCHERICHIA COLI; FEMALE; FEMALE GENITAL TRACT INFLAMMATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUCOSAL IMMUNITY; UTERINE CERVIX CARCINOMA IN SITU; VAGINA SECRETION; VAGINAL LAVAGE; WART VIRUS;

ADOLESCENT; ADULT; AGED; BLOTTING, SOUTHERN; CERVICAL INTRAEPITHELIAL NEOPLASIA; CROSS-SECTIONAL STUDIES; CYTOKINES; ESCHERICHIA COLI; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; INTERLEUKIN-8; MIDDLE AGED; NEW YORK; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; REPRODUCTIVE TRACT INFECTIONS; RISK FACTORS; THERAPEUTIC IRRIGATION; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84863803798     PISSN: 01485717     EISSN: 15374521     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e318255aeef     Document Type: Article

References (30)

1. Hariri S, Unger ER, Sternberg M, et al. Prevalence of genital human papillomavirus among females in the United States, the national health and nutrition examination survey, 2003-2006. J Infect Dis 2011; 204:566-73.
2. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet 2007; 370:890-907. (Pubitemid 47371147)
3. Dunne EF, Sternberg M, Markowitz LE, et al. Human papillomavirus (HPV) 6, 11, 16, and 18 prevalence among females in the United States-National health and nutrition examination survey, 2003-2006: Opportunity to measure HPV vaccine impact? J Infect Dis 2011; 204:562-565.
4. Strickler HD, Burk RD, Fazzari M, et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst 2005; 97:577-586. (Pubitemid 40723785)
5. Wang C, Wright TC, Denny L, et al. Rapid rise in detection of human papillomavirus (HPV) infection soon after incident HIV infection among South African women. J Infect Dis 2011; 203:479-486.
6. Smith-McCune KK, Shiboski S, Chirenje MZ, et al. Type-specific cervico-vaginal human papillomavirus infection increases risk of HIV acquisition independent of other sexually transmitted infections. PLoS One 2010; 5:e10094.
7. Edwards RP, Kuykendall K, Crowley-Nowick P, et al. T lymphocytes infiltrating advanced grades of cervical neoplasia. CD8-positive cells are recruited to invasion. Cancer 1995; 76:1411-1415.
8. Kobayashi A, Greenblatt RM, Anastos K, et al. Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer Res 2004; 64:6766-6774. (Pubitemid 39297940)
9. Cole AM, Cole AL. Antimicrobial polypeptides are key anti- HIV-1 effector molecules of cervicovaginal host defense. Am J Reprod Immunol 2008; 59:27-34. (Pubitemid 350285580)
10. Buck CB, Day PM, Thompson CD, et al. Human alpha-defensins block papillomavirus infection. Proc Natl Acad Sci U S A 2006; 103:1516-1521. (Pubitemid 43191197)
11. McNeely TB, Dealy M, Dripps DJ, et al. Secretory leukocyte protease inhibitor: A human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest 1995; 96:456-464.
12. John M, Keller MJ, Fam EH, et al. Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection. J Infect Dis 2005; 192:1731-1740. (Pubitemid 41587823)
13. Novak RM, Donoval BA, Graham PJ, et al. Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infection. Clin Vaccine Immunol 2007; 14:1102-1107. (Pubitemid 47518076)
14. Fakioglu E, Wilson SS, Mesquita PM, et al. Herpes simplex virus downregulates secretory leukocyte protease inhibitor: A novel immune evasion mechanism. J Virol 2008; 82:9337-9344.
15. Low N, Chersich MF, Schmidlin K, et al. Intravaginal practices, bacterial vaginosis, and HIV infection in women: Individual participant data meta-analysis. PLoS Med 2011; 8:e1000416.
16. Crowley-Nowick PA, Ellenberg JH, Vermund SH, et al. Cytokine profile in genital tract secretions from female adolescents: Impact of human immunodeficiency virus, human papillomavirus, and other sexually transmitted pathogens. J Infect Dis 2000; 181:939-945. (Pubitemid 30194477)
17. Behbakht K, Friedman J, Heimler I, et al. Role of the vaginal microbiological ecosystem and cytokine profile in the promotion of cervical dysplasia: A case-control study. Infect Dis Obstet Gynecol 2002; 10:181-186. (Pubitemid 36207209)
18. Castle PE, Schiffman M, Gravitt PE, et al. Comparisons of HPV DNA detection by MY09/11 PCR methods. J Med Virol 2002; 68:417-423.
19. Valore EV, Park CH, Igreti SL, et al. Antimicrobial components of vaginal fluid. Am J Obstet Gynecol 2002; 187:561-568.
20. Chaturvedi AK, Katki HA, Hildesheim A, et al. Human papillomavirus infection with multiple types: Pattern of coinfection and risk of cervical disease. J Infect Dis 2011; 203:910-920.
21. Li Q, Estes JD, Schlievert PM, et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature 2009; published online 4 March.
22. Ferreira VH, Nazli A, Khan G, et al. Endometrial epithelial cell responses to coinfecting viral and bacterial pathogens in the genital tract can activate the HIV-1 LTR in an NF{kappa}B-and AP-1-dependent manner. J Infect Dis 2011; 204:299-308.
23. Henning TR, Kissinger P, Lacour N, et al. Elevated cervical white blood cell infiltrate is associated with genital HIV detection in a longitudinal cohort of antiretroviral therapy-adherent women. J Infect Dis 2010; 202:1543-1552.
24. Mitchell C, Hitti J, Paul K, et al. Cervicovaginal shedding of HIV type 1 is related to genital tract inflammation independent of changes in vaginal microbiota. AIDS Res Hum Retroviruses 2011; 27:35-39.
25. Nees M, Geoghegan JM, Hyman T, et al. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J Virol 2001; 75:4283-4296. (Pubitemid 32410141)
26. Hubert P, Herman L, Maillard C, et al. Defensins induce the recruitment of dendritic cells in cervical human papillomavirus-associated (pre)neoplastic lesions formed in vitro and transplanted in vivo. FASEB J 2007; 21:2765-2775. (Pubitemid 47372744)
27. Pioli PA, Weaver LK, Schaefer TM, et al. Lipopolysaccharide-induced IL-1 beta production by human uterine macrophages up-regulates uterine epithelial cell expression of human beta-defensin 2. J Immunol 2006; 176:6647-6655. (Pubitemid 43787848)
28. King AE, Fleming DC, Critchley HO, et al. Differential expression of the natural antimicrobials, beta-defensins 3 and 4, in human endometrium. J Reprod Immunol 2003; 59:1-16. (Pubitemid 36918496)
29. Zapata W, Rodriguez B, Weber J, et al. Increased levels of human beta-defensins mRNA in sexually HIV-1 exposed but uninfected individuals. Curr HIV Res 2008; 6:531-538.
30. Farquhar C, VanCott TC, Mbori-Ngacha DA, et al. Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk. J Infect Dis 2002; 186:1173-1176. (Pubitemid 35177123)